CA
ALLO icon

Calton & Associates’s Allogene Therapeutics ALLO Stock Holding History

Calton & Associates’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,170
Closed -$27.3K – 421
2026
Q1 		$27.3K Buy
+11,170
New +$22.4K ﹤0.01% 437
2024
Q1 		– Sell
-21,060
Closed -$67.6K – 193
2023
Q4 		$67.6K Buy
+21,060
New +$59.7K 0.03% 241
2023
Q3 		– Sell
-22,907
Closed -$114K – 110
2023
Q2 		$114K Sell
22,907
-854
-4% -$4.62K 0.05% 203
2023
Q1 		$117K Buy
23,761
+7,447
+46% +$47.8K 0.05% 226
2022
Q4 		$103K Buy
16,314
+4,846
+42% +$44.9K 0.04% 272
2022
Q3 		$123K Sell
11,468
-5,884
-34% -$80K 0.07% 200
2022
Q2 		$197K Sell
17,352
-977
-5% -$8.67K 0.11% 220
2022
Q1 		$166K Buy
+18,329
New +$191K 0.05% 333
2021
Q4 		– Sell
-9,546
Closed -$245K – 368
2021
Q3 		$245K Buy
+9,546
New +$227K 0.05% 332
2021
Q2 		– Sell
-6,067
Closed -$214K – 408
2021
Q1 		$214K Buy
+6,067
New +$205K 0.04% 361

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Calton & Associates's ALLO Position: Q2 2026 in Review

Calton & Associates sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 11,170 shares — an estimated $27.3K sold.

Calton & Associates first reported a position in ALLO in Q1 2021 and held it in 10 quarters. The position peaked at $245K in Q3 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Calton & Associates reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Calton & Associates sold 11,170 Allogene Therapeutics shares in Q2 2026, an estimated $27.3K.
  • Calton & Associates first reported a position in Allogene Therapeutics in Q1 2021 and held it in 10 quarters.
  • Calton & Associates's Allogene Therapeutics position peaked at $245K in Q3 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.